- USA
- clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections
- Investment Period: 7 years
- IPO, NYSE, May 2007
Pharmasset Inc., based in Princeton, New Jersey, is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (“HCV”). TVM Capital initially invested in Pharmasset in 2001 as the second institutional investor. Dr. Alexandra Goll served on the company’s board until the IPO in April 2007.
Pharmasset was the best performing NASDAQ biotechnology stock of the 2007 IPO vintage. TVM Capital Life Science began selling its shares of Pharmasset during the first quarter of 2008 and sold all of its remaining shares on June 30th producing venture-like returns for the invested funds.